Stock Events

Stock Events

Histogen 

$0.020000
23
-$0.01-33.33% Thursday 20:00

Statistics

Day High
0.2125
Day Low
0.2125
52W High
0.55
52W Low
0.02
Volume
200
Avg. Volume
622
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22NovExpected
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Q2 2024
Q3 2024
-0.9
-0.76
-0.63
-0.49
Expected EPS
N/A
Actual EPS
N/A

Financials

-294.75%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
3.77MRevenue
-11.11MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ocugen
OCGN
Mkt Cap497.63M
Ocugen is involved in developing gene therapies for retinal diseases, competing with Histogen's regenerative medicine approach.
Pfizer
PFE
Mkt Cap137.76B
Pfizer, with its broad range of healthcare products, including treatments in dermatology and regenerative medicine, competes in some areas with Histogen.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals focuses on regenerative medicine and biologics, directly competing with Histogen's product offerings.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie, through its aesthetics portfolio, competes with Histogen's hair growth and dermatological products.
AMGEN
AMGN
Mkt Cap196.12B
Amgen, with its focus on human therapeutics, has products that compete in the regenerative medicine space with Histogen.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical targets rare diseases with gene therapies, overlapping with Histogen's regenerative medicine focus.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences, with its work in cell therapy and regenerative medicine, competes with Histogen's approach to treatment.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals, focusing on cell and genetic therapies, has a competitive edge in the same field as Histogen.
Novartis
NVS
Mkt Cap293.94B
Novartis, with its advanced therapy medicinal products, competes in the regenerative medicine and dermatology space against Histogen.

About

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Show more...
CEO
Ms. Susan A. Knudson
Employees
7
Country
United States
ISIN
US43358Y2028

Listings

0 Comments

Share your thoughts

FAQ

What is Histogen stock price today?▼
The current price of HSTO is $0.02 USD — it has decreased by -33.33% in the past 24 hours. Watch Histogen stock price performance more closely on the chart.
What is Histogen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Histogen stocks are traded under the ticker HSTO.
What is Histogen revenue for the last year?▼
Histogen revenue for the last year amounts to 3.77M USD.
What is Histogen net income for the last year?▼
HSTO net income for the last year is -11.11M USD.
How many employees does Histogen have?▼
As of July 29, 2026, the company has 7 employees.
In which sector is Histogen located?▼
Histogen operates in the Health & Wellness sector.
When did Histogen complete a stock split?▼
The last stock split for Histogen was on June 03, 2022 with a ratio of 1:20.
Where is Histogen headquartered?▼
Histogen is headquartered in San Diego, United States.